Logo image of ACB

AURORA CANNABIS INC (ACB) Stock Fundamental Analysis

NASDAQ:ACB - CA05156X8504 - Common Stock

4.97 USD
-0.08 (-1.58%)
Last: 9/10/2025, 8:00:00 PM
4.9865 USD
+0.02 (+0.33%)
After Hours: 9/10/2025, 8:00:00 PM
Fundamental Rating

3

Taking everything into account, ACB scores 3 out of 10 in our fundamental rating. ACB was compared to 195 industry peers in the Pharmaceuticals industry. ACB may be in some trouble as it scores bad on both profitability and health. ACB is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year ACB has reported negative net income.
ACB had a positive operating cash flow in the past year.
ACB had negative earnings in 4 of the past 5 years.
In the past 5 years ACB reported 4 times negative operating cash flow.
ACB Yearly Net Income VS EBIT VS OCF VS FCFACB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -1B -2B -3B

1.2 Ratios

ACB's Return On Assets of -2.32% is fine compared to the rest of the industry. ACB outperforms 75.90% of its industry peers.
Looking at the Return On Equity, with a value of -3.53%, ACB is in the better half of the industry, outperforming 77.44% of the companies in the same industry.
Industry RankSector Rank
ROA -2.32%
ROE -3.53%
ROIC N/A
ROA(3y)-55.32%
ROA(5y)-62.11%
ROE(3y)-90.28%
ROE(5y)-91.51%
ROIC(3y)N/A
ROIC(5y)N/A
ACB Yearly ROA, ROE, ROICACB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50 -100 -150 -200 -250

1.3 Margins

ACB's Gross Margin of 4.04% is in line compared to the rest of the industry. ACB outperforms 48.72% of its industry peers.
ACB's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for ACB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 4.04%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-29.39%
ACB Yearly Profit, Operating, Gross MarginsACB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -200 -400 -600 -800 -1K

More info and screens

3

2. Health

2.1 Basic Checks

ACB does not have a ROIC to compare to the WACC, probably because it is not profitable.
ACB has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, ACB has less shares outstanding
The debt/assets ratio for ACB has been reduced compared to a year ago.
ACB Yearly Shares OutstandingACB Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
ACB Yearly Total Debt VS Total AssetsACB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B 4B 5B

2.2 Solvency

ACB has an Altman-Z score of -9.38. This is a bad value and indicates that ACB is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -9.38, ACB is doing worse than 67.69% of the companies in the same industry.
ACB has a Debt/Equity ratio of 0.07. This is a healthy value indicating a solid balance between debt and equity.
ACB has a Debt to Equity ratio (0.07) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF N/A
Altman-Z -9.38
ROIC/WACCN/A
WACC9.41%
ACB Yearly LT Debt VS Equity VS FCFACB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 1B 2B 3B 4B

2.3 Liquidity

A Current Ratio of 2.97 indicates that ACB has no problem at all paying its short term obligations.
ACB's Current ratio of 2.97 is in line compared to the rest of the industry. ACB outperforms 55.90% of its industry peers.
ACB has a Quick Ratio of 1.51. This is a normal value and indicates that ACB is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.51, ACB is doing worse than 60.51% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.97
Quick Ratio 1.51
ACB Yearly Current Assets VS Current LiabilitesACB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 44.79% over the past year.
The Revenue has grown by 28.42% in the past year. This is a very strong growth!
Measured over the past years, ACB shows a small growth in Revenue. The Revenue has been growing by 6.94% on average per year.
EPS 1Y (TTM)44.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-307.69%
Revenue 1Y (TTM)28.42%
Revenue growth 3Y11.86%
Revenue growth 5Y6.94%
Sales Q2Q%17.48%

3.2 Future

ACB is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 103.58% yearly.
ACB is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.42% yearly.
EPS Next Y-288.53%
EPS Next 2Y130.64%
EPS Next 3Y81.3%
EPS Next 5Y103.58%
Revenue Next Year8.72%
Revenue Next 2Y5.83%
Revenue Next 3Y6.05%
Revenue Next 5Y7.42%

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
ACB Yearly Revenue VS EstimatesACB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 100M 200M 300M 400M 500M
ACB Yearly EPS VS EstimatesACB Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -5 -10

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

ACB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
The Price/Forward Earnings ratio is 25.81, which means the current valuation is very expensive for ACB.
Compared to the rest of the industry, the Price/Forward Earnings ratio of ACB indicates a somewhat cheap valuation: ACB is cheaper than 71.79% of the companies listed in the same industry.
When comparing the Price/Forward Earnings ratio of ACB to the average of the S&P500 Index (22.54), we can say ACB is valued inline with the index average.
Industry RankSector Rank
PE N/A
Fwd PE 25.81
ACB Price Earnings VS Forward Price EarningsACB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ACB Per share dataACB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

A more expensive valuation may be justified as ACB's earnings are expected to grow with 81.30% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y130.64%
EPS Next 3Y81.3%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ACB!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AURORA CANNABIS INC

NASDAQ:ACB (9/10/2025, 8:00:00 PM)

After market: 4.9865 +0.02 (+0.33%)

4.97

-0.08 (-1.58%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-06 2025-08-06/bmo
Earnings (Next)11-04 2025-11-04/bmo
Inst Owners19.7%
Inst Owner Change-26.77%
Ins Owners0.05%
Ins Owner ChangeN/A
Market Cap279.56M
Analysts73.33
Price Target5.8 (16.7%)
Short Float %10.5%
Short Ratio3.75
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-321.48%
Min EPS beat(2)-426.74%
Max EPS beat(2)-216.23%
EPS beat(4)1
Avg EPS beat(4)935.07%
Min EPS beat(4)-426.74%
Max EPS beat(4)4494.06%
EPS beat(8)3
Avg EPS beat(8)450.07%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)0.04%
Min Revenue beat(2)-0.84%
Max Revenue beat(2)0.93%
Revenue beat(4)3
Avg Revenue beat(4)7.13%
Min Revenue beat(4)-0.84%
Max Revenue beat(4)14.66%
Revenue beat(8)6
Avg Revenue beat(8)3.86%
Revenue beat(12)7
Avg Revenue beat(12)2.68%
Revenue beat(16)9
Avg Revenue beat(16)2.74%
PT rev (1m)-9.89%
PT rev (3m)-24.29%
EPS NQ rev (1m)-67.44%
EPS NQ rev (3m)55.57%
EPS NY rev (1m)-127.78%
EPS NY rev (3m)-127.78%
Revenue NQ rev (1m)-1.52%
Revenue NQ rev (3m)10.44%
Revenue NY rev (1m)-1.54%
Revenue NY rev (3m)-2.5%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 25.81
P/S 1.08
P/FCF N/A
P/OCF 20.7
P/B 0.7
P/tB 0.84
EV/EBITDA N/A
EPS(TTM)-0.25
EYN/A
EPS(NY)0.19
Fwd EY3.87%
FCF(TTM)0
FCFYN/A
OCF(TTM)0.24
OCFY4.83%
SpS4.61
BVpS7.1
TBVpS5.94
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -2.32%
ROE -3.53%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 4.04%
FCFM N/A
ROA(3y)-55.32%
ROA(5y)-62.11%
ROE(3y)-90.28%
ROE(5y)-91.51%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-29.39%
F-Score6
Asset Turnover0.43
Health
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 81.56%
Cap/Sales 5.24%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.97
Quick Ratio 1.51
Altman-Z -9.38
F-Score6
WACC9.41%
ROIC/WACCN/A
Cap/Depr(3y)56.47%
Cap/Depr(5y)106.5%
Cap/Sales(3y)8.76%
Cap/Sales(5y)35.04%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)44.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-307.69%
EPS Next Y-288.53%
EPS Next 2Y130.64%
EPS Next 3Y81.3%
EPS Next 5Y103.58%
Revenue 1Y (TTM)28.42%
Revenue growth 3Y11.86%
Revenue growth 5Y6.94%
Sales Q2Q%17.48%
Revenue Next Year8.72%
Revenue Next 2Y5.83%
Revenue Next 3Y6.05%
Revenue Next 5Y7.42%
EBIT growth 1Y4.54%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year150.01%
EBIT Next 3Y29.77%
EBIT Next 5Y25.22%
FCF growth 1Y92.97%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y208.3%
OCF growth 3YN/A
OCF growth 5YN/A